TomoTherapy Incorporated announced today that France's Institute
Curie Hospital has acquired the first TomoTherapy Hi-Art system to be
used in France. The Institute Curie Hospital announced the acquisition
with a tour of the treatment area and a reception hosted by Professor
Claude Huriet, President of the Institute Curie, on March 7th, 2007.
Notable attendees included Professor Dominque Maranchi, President of
the National Institute of Cancer (INCA) and Marc Lipinski,
Vice-President of the Regional Council, IIe-de-France.
A private foundation comprised of France's largest cancer research
center and a leading public hospital, the Institute Curie was founded
in 1909 by Marie Curie. Since receiving state approval in 1921, the
Institute Curie has made developing innovative and individualized
treatments, and ensuring availability of the most advanced techniques,
among its chief priorities.
"We are pleased to have the TomoTherapy Hi-Art system being used
by a pioneering institution so notably linked to the field of
radiation," said TomoTherapy Inc. CEO, Dr. Fred Robertson.
The decision by the Institute Curie Hospital to install the
TomoTherapy Hi-Art system follows calls for research proposals
launched by the National Cancer Institute in July 2005 to promote
implementation of image-guided radiation therapy technology that was
not previously available in France. Two other centers in France,
Nantes and Bordeaux, intend to install the TomoTherapy Hi-Art system
as a result of the proposals' recommendations.
About TomoTherapy Incorporated
TomoTherapy Incorporated has developed, manufactures and sells the
Hi-Art(R) system, one of the most advanced and versatile radiation
therapy systems commercially available for the treatment of a wide
variety of cancers. TomoTherapy Incorporated markets the Hi-Art(R)
system to hospitals and cancer treatment centers in North America,
Europe and Asia.
